schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
the report was compiled by outside researchers who went into the fda�s own database of �serious adverse [medical-drug] events.�.
- .
while all of the drugs work on cgrp, they don�t all work the same way. three of them target the cgrp molecule itself. aimovig goes after cgrp's receptor in the brain...